Daraxonrasib (RMC-6236) is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential. RMC-6236 exhibits strong anticancer efficacy in RAS-addicted cell lines, especially those with mutations at codon 12 of KRAS.

Daraxonrasib (RMC-6236) is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential. RMC-6236 exhibits strong anticancer efficacy in RAS-addicted cell lines, especially those with mutations at codon 12 of KRAS.

Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD).

Gepotidacin (GSK2140944) is a triazaacenaphthylene that inhibits bacterial type II topoisomerases. It has the potential to treat conventional and biothreat pathogens, including Gram-positive bacteria and methicillin-resistant Staphylococcus aureus (MRSA).

MFI8 is a small molecule inhibitor of mitofusin-1 (MFN1) and mitofusin-2 (MFN2). It significantly reduces mitochondrial aspect ratio, inhibiting mitochondrial fusion and subsequently promoting mitochondrial fission and can be used in research on disorders with impaired mitochondrial dynamics.

MFI8 is a small molecule inhibitor of mitofusin-1 (MFN1) and mitofusin-2 (MFN2). It significantly reduces mitochondrial aspect ratio, inhibiting mitochondrial fusion and subsequently promoting mitochondrial fission and can be used in research on disorders with impaired mitochondrial dynamics.

MFI8 is a small molecule inhibitor of mitofusin-1 (MFN1) and mitofusin-2 (MFN2). It significantly reduces mitochondrial aspect ratio, inhibiting mitochondrial fusion and subsequently promoting mitochondrial fission and can be used in research on disorders with impaired mitochondrial dynamics.

MFI8 is a small molecule inhibitor of mitofusin-1 (MFN1) and mitofusin-2 (MFN2). It significantly reduces mitochondrial aspect ratio, inhibiting mitochondrial fusion and subsequently promoting mitochondrial fission and can be used in research on disorders with impaired mitochondrial dynamics.

Edralbrutinib (TG-1701) is an irreversible, highly specific, and potent inhibitor of Bruton’s tyrosine kinase (BTK). TG-1701 shows similar efficacy but greater selectivity compared to the first-in-class BTK inhibitor ibrutinib, with a Kd value of 3 nmol/L, in both in vitro and in vivo models of B-cell non-Hodgkin lymphoma (B-NHL).

Edralbrutinib (TG-1701) is an irreversible, highly specific, and potent inhibitor of Bruton’s tyrosine kinase (BTK). TG-1701 shows similar efficacy but greater selectivity compared to the first-in-class BTK inhibitor ibrutinib, with a Kd value of 3 nmol/L, in both in vitro and in vivo models of B-cell non-Hodgkin lymphoma (B-NHL).